GPT and metabolic dysfunction-associated steatohepatitis: In a previous phase 2 clinical trial (NCT00492700; Table 1) on 63 patients with NASH, rosiglitazone (8 mg/day) taken for one year reduced blood ALT levels and improved fatty degeneration, but had no significant effects on liver fibrosis or NASH activity scores [47].